Video Content Compliance Monitor

Continuous FDA regulatory compliance monitoring for promotional video content

Configure Alerts How It Works
Monitoring Active
Last FDA Check: Mar 16, 2026
Algorithm: v3.2 (14 patterns from 34 letters)
Brands Monitored: 31
31
Total Assets
28
Active Alerts
66
Avg Score
6
At Risk
22
Caution
1
Lower Risk

Portfolio Risk Map

At Risk
Fasenra (59)59Jublia (55)55BRUKINSA (58)58FABHALTA (60)60Sotyktu (54)54Cosentyx (59)59
Caution
Calquence (69)69Jardiance (67)67Velsipity (62)62Contrave (68)68Farxiga (66)66Austedo XR (72)72Camzyos (64)64Kesimpta (66)66Linzess (70)70Qulipta (65)65Ingrezza (68)68Attruby (62)62COBENFY (68)68Vyvgart Hytrulo (gMG) (75)75Vyvgart Hytrulo (CIDP) (61)61Neffy (62)62Wegovy Pill (72)72TREMFYA (70)70Dupixent (63)63Keytruda (67)67Eliquis (74)74Rinvoq (65)65
Lower Risk
Trelegy Ellipta (79)79

Compliance Risk Drivers

Average dimension scores across portfolio (lower = higher risk)

Visual Distraction
49
49
Efficacy
69
69
Fair Balance
69
69
Adequate Provision
89
89
Portfolio Brands
Calquence
AstraZeneca Pharmaceuticals LP
69
Caution 5 patterns Visual Distraction FDA Letter
DOC-2025-001234
Jardiance
Boehringer Ingelheim Pharmaceuticals
67
Caution 4 patterns Visual Distraction FDA Letter
DOC-2025-001245
Velsipity
Pfizer
62
Caution 4 patterns Visual Distraction FDA Letter
DOC-2025-001236
Contrave
Currax Pharmaceuticals
68
Caution 4 patterns Visual Distraction FDA Letter
DOC-2025-001237
Farxiga
AstraZeneca Pharmaceuticals LP
66
Caution 4 patterns Visual Distraction FDA Letter
Austedo XR
Teva Pharmaceuticals
72
Caution 3 patterns Fair Balance FDA Letter
DOC-2025-001238
Camzyos
Bristol Myers Squibb
64
Caution 2 patterns Visual Distraction FDA Letter
DOC-2025-001239
Kesimpta
Novartis
66
Caution 6 patterns Visual Distraction FDA Letter
DOC-2025-001247
Fasenra
AstraZeneca
59
At Risk 5 patterns Visual Distraction FDA Letter
DOC-2025-001243
Linzess
AbbVie/Ironwood
70
Caution 5 patterns Visual Distraction FDA Letter
DOC-2025-001241
Jublia
Bausch Health
55
At Risk 6 patterns Visual Distraction FDA Letter
DOC-2025-001235
Qulipta
AbbVie
65
Caution 2 patterns Visual Distraction FDA Letter
DOC-2025-001242
Ingrezza
Neurocrine Biosciences
68
Caution 3 patterns Visual Distraction FDA Letter
DOC-2025-001246
Attruby
Alnylam Pharmaceuticals
62
Caution 6 patterns Visual Distraction FDA Letter
DOC-2025-001244
COBENFY
Karuna Therapeutics (Bristol Myers Squibb)
68
Caution 3 patterns Visual Distraction FDA Letter
BRUKINSA
BeiGene (BeOne Medicines)
58
At Risk 4 patterns Visual Distraction FDA Letter
NEXLIZET
Esperion Therapeutics, Inc.
0
Pending FDA Letter
Vyvgart Hytrulo (gMG)
argenx
75
Caution 2 patterns Visual Distraction FDA Letter
Vyvgart Hytrulo (CIDP)
argenx
61
Caution 3 patterns Visual Distraction FDA Letter
Neffy
ARS Pharmaceuticals
62
Caution 2 patterns Visual Distraction FDA Letter
Wegovy Pill
Novo Nordisk
72
Caution 2 patterns Visual Distraction FDA Letter
TREMFYA
Janssen Biotech (Johnson & Johnson)
70
Caution 4 patterns Visual Distraction FDA Letter
FABHALTA
Novartis Pharmaceuticals
60
At Risk 5 patterns Visual Distraction FDA Letter
Dupixent
Sanofi/Regeneron
63
Caution 6 patterns Visual Distraction
Keytruda
Merck
67
Caution 5 patterns Visual Distraction
Eliquis
BMS/Pfizer
74
Caution 3 patterns Visual Distraction
Rinvoq
AbbVie
65
Caution 4 patterns Visual Distraction
Trelegy Ellipta
GSK
79
Lower Risk 2 patterns Visual Distraction
Sotyktu
BMS
54
At Risk 6 patterns Visual Distraction
Cosentyx
Novartis
59
At Risk 6 patterns Visual Distraction
Vonjo
Swedish Orphan Biovitrum (Sobi)
0
Pending FDA Letter

Powered by cQuenced